FDA approves drug for treating postpartum depression

FDA

Postpartum depression affects about 400,000 American women a year.

Posted: Mar 19, 2019 7:58 PM

TRENTON, N.J. (AP) - The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth.

The agency on Tuesday approved Sage Therapeutics' Zulresso (ZUHL'-ress-oh), an IV drug given over 2 ½ days.

In a company-funded study of new mothers with moderate or severe postpartum depression, half the women given Zulresso had depression end within 2 ½ days, about double the rate of those in a comparison group given dummy treatments.

Postpartum depression affects about 400,000 American women a year. It's often treated with antidepressants, though they can take several weeks to help and don't always work.

Sage said Zulresso will cost $34,000 without insurance, plus costs for the stay in a hospital or infusion center.

Huntsville
Partly Cloudy
87° wxIcon
Hi: 88° Lo: 67°
Feels Like: 91°
Florence
Partly Cloudy
91° wxIcon
Hi: 92° Lo: 67°
Feels Like: 95°
Fayetteville
Partly Cloudy
87° wxIcon
Hi: 89° Lo: 69°
Feels Like: 91°
Decatur
Partly Cloudy
86° wxIcon
Hi: 89° Lo: 68°
Feels Like: 91°
Scottsboro
Partly Cloudy
83° wxIcon
Hi: 87° Lo: 68°
Feels Like: 87°
WAAY Radar
WAAY WAAY-TV Cam
WAAY Temperatures

 

Community Events